Skip to main content
Glama

Github_private

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. Added

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent annotations, the description discloses multi-step cascading lookups, graceful degradation when GLEIF/OpenFIGI are unavailable, explicit `unresolved` reporting, `figi_candidates` ambiguity behavior, source labeling, and ISIN-to-LEI mapping. No contradictions with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and long, but nearly every sentence adds operational value. It is front-loaded with trigger examples and the 'Use FIRST' directive; some structural formatting would help, but the content is justified by the tool's complexity.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description compensates well by explaining return semantics: unresolved identifiers, candidate lists, source labels, and graceful degradation. An agent has enough detail to call the tool correctly and interpret ambiguous results.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even though schema coverage is 100%, the description adds critical invocation guidance: pass the entity name only, never the full noun phrase, with bond issuer examples. It also explains type-specific semantics like ISIN resolution for non-US issuers and drug RxCUI behavior, which prevents real mistakes.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool resolves user-spoken names to canonical/official identifiers and enumerates supported entity types (company, drug). The quoted natural-language triggers make the purpose unmistakable and distinguish it from generic search or research tools.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly says 'Use FIRST whenever you have a name but need an ID' and gives concrete example queries. It does not explicitly name alternative tools or exclusion conditions, but the usage context is clear enough for routing decisions.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Github_private toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation2/5

There is significant overlap among many tools: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, and validate_claim all serve query-answer purposes with subtle differences, and multiple polymarket tools (polymarket_arbitrage, polymarket_edges, polymarket_edge_tracker, polymarket_fill_risk, polymarket_kalshi_spread) cover similar arbitrage/mispricing territory. Additionally, ai_visibility_check and scan_competitor_ai_presence clearly overlap, making it hard to pick the right one.

Naming Consistency2/5

Tool names follow no consistent pattern. Some use a gh_ prefix (gh_get_file, gh_get_repo, etc.), others are descriptive phrases (ask_pipeworx, compare_entities, bet_research), and a few are plain verbs (remember, recall, forget, subscribe, unsubscribe). The mixed conventions and varied verb/noun styles make the set feel disjointed.

Tool Count3/5

At 37 tools, the count is high but still within a usable range. However, the server is named 'Github_private' yet includes only 7 GitHub-specific tools and 30+ unrelated tools (Pipeworx data, Polymarket betting, memory, etc.). This suggests the server aggregates multiple unrelated domains, making the count feel bloated for its apparent GitHub purpose.

Completeness2/5

Given the server name, the GitHub tool surface is severely incomplete: there are no create/update/delete operations for repos, no PR creation or merging, no issue comments, no branches, and no search across repos. The Pipeworx side is fairly comprehensive, but the mismatch between the server name and the actual tool set leaves major gaps for expected GitHub workflows.

Resources